 |
|
|
| |
Sustained Viral Suppression After Switch to Bictegravir/Emtricitabine/Tenofovir
Alafenamide Among Clinical Trial Participants With Preexisting M184V/I
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Kristen Andreatta, Rima Acosta, Michelle L. D'Antoni, Danielle P. Porter, Silvia Chang, Ross Martin, Madeleine Willkom, Ian McNicholl, Joel Gallant,
Cheryl Pikora, Hiba Graham, Sean Collins, Hal Martin, Kirsten L. White - Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
